Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEOGENOMICS INCNEO · Entity 2096 | VP and Chief Culture Officer | December 30, 2021 | December 30, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEOGENOMICS INC
Report date December 30, 2021 · Filed December 30, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 48,615 |
Reported balance
After 2021-12-30 transaction · row 1
1 source rowRow 1 · 2021-12-30 · Grant · Acquired 21,400 · Balance 48,615 F1: On December 30, 2021, Ms. Balliet was granted 21,400 restricted stock awards. These awards vest ratably over three years with the first tranche vesting on December 31, 2022. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.52 · Expires 2022-04-28 | Direct | 7,000 |
Reported balance
Holding disclosure · report date 2021-12-30 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 7,000 F2: On April 28, 2017, Ms. Balliet was granted 60,000 stock options. These options vested ratably over the first three anniversaries of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.03 · Expires 2023-02-26 | Direct | 33,334 |
Reported balance
Holding disclosure · report date 2021-12-30 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 33,334 F3: On February 26, 2018, Ms. Balliet was granted 72,500 stock options. These options vested ratably over the first three anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.60 · Expires 2024-03-01 | Direct | 17,496 |
Reported balance
Holding disclosure · report date 2021-12-30 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 17,496 F4: On March 1, 2019, Ms. Balliet was granted 17,496 stock options. These options vest ratably over the first four anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.33 · Expires 2027-03-02 | Direct | 15,006 |
Reported balance
Holding disclosure · report date 2021-12-30 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 15,006 F5: On March 2, 2020, Ms. Balliet was granted 15,006 stock options. These options vest ratably over the first four anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.17 · Expires 2028-03-02 | Direct | 10,551 |
Reported balance
Holding disclosure · report date 2021-12-30 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 10,551 F6: On March 2, 2021, Ms. Balliet was granted 10,551 stock options. These options vest ratably over the first four anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.95 · Expires 2028-07-05 | Direct | 4,050 |
Reported balance
Holding disclosure · report date 2021-12-30 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 4,050 F7: On July 5, 2021, Ms. Balliet was granted 4,050 stock options. These options vest ratably over the first four anniversary dates of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 30, 2021, Ms. Balliet was granted 21,400 restricted stock awards. These awards vest ratably over three years with the first tranche vesting on December 31, 2022.
F2: On April 28, 2017, Ms. Balliet was granted 60,000 stock options. These options vested ratably over the first three anniversaries of the grant date.
F3: On February 26, 2018, Ms. Balliet was granted 72,500 stock options. These options vested ratably over the first three anniversary dates of the grant date.
F4: On March 1, 2019, Ms. Balliet was granted 17,496 stock options. These options vest ratably over the first four anniversary dates of the grant date.
F5: On March 2, 2020, Ms. Balliet was granted 15,006 stock options. These options vest ratably over the first four anniversary dates of the grant date.
F6: On March 2, 2021, Ms. Balliet was granted 10,551 stock options. These options vest ratably over the first four anniversary dates of the grant date.
F7: On July 5, 2021, Ms. Balliet was granted 4,050 stock options. These options vest ratably over the first four anniversary dates of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2018 Filed May 17, 2018 19:35 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $4.78 | $0.00 |
DisclosureSEC source: 0001628280-18-006899 · wf-form4_152658569707611.xml · derivative · entry 4 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 13,000 shares Expires 2020-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On May 4, 2015, Jennifer Balliet was granted 120,000 stock options,these options vest ratably over the first three anniversary dates of the grant date. On March 26, 2018, 7,000 of these options were exercised leaving a balance of 113,000 options. Read SEC document |
| May 15, 2018 Filed May 17, 2018 19:35 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 6,500 | $11.26 | $73,190.00 |
DisclosureSEC source: 0001628280-18-006899 · wf-form4_152658569707611.xml · nonDerivative · entry 3 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| May 15, 2018 Filed May 17, 2018 19:35 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 6,500 | $11.21 | $72,865.00 |
DisclosureSEC source: 0001628280-18-006899 · wf-form4_152658569707611.xml · nonDerivative · entry 2 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Read SEC document |
| May 15, 2018 Filed May 17, 2018 19:35 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 13,000 | $4.78 | $62,140.00 |
DisclosureSEC source: 0001628280-18-006899 · wf-form4_152658569707611.xml · nonDerivative · entry 1 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 28, 2018 Filed Mar 28, 2018 20:57 UTC | NEOGENOMICS INC NEO · Entity 2096 | Disposition to issuerCommon Stock | 7,000 | $8.20 | $57,400.00 |
DisclosureSEC source: 0001628280-18-003729 · wf-form4_152227064609700.xml · nonDerivative · entry 2 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| March 28, 2018 Filed Mar 28, 2018 20:57 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 7,000 | $4.78 | $33,460.00 |
DisclosureSEC source: 0001628280-18-003729 · wf-form4_152227064609700.xml · nonDerivative · entry 1 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 26, 2018 Filed Mar 28, 2018 20:57 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,000 | $4.78 Strike: $4.78 | $33,460.00 |
DisclosureSEC source: 0001628280-18-003729 · wf-form4_152227064609700.xml · derivative · entry 3 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,000 Underlying: Common Stock · 7,000 shares Expires 2020-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On May 4, 2015, Jennifer Balliet was granted stock options, these options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 23:57 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 72,500 | $8.03 Strike: $8.03 | $582,175.00 |
DisclosureSEC source: 0001209191-18-014681 · doc4.xml · derivative · entry 5 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,500 Underlying: Common Stock · 72,500 shares Expires 2023-02-26 F7 · derivative.exercise_date: On February 26, 2018, Jennifer Balliet was granted 72,500 stock options which vested ratably over the first three anniversary dates of the grant date. Read SEC document |
| August 24, 2017 Filed Aug 25, 2017 18:44 UTC | NEOGENOMICS INC NEO · Entity 2096 | OtherStock Option (Right to Buy) · Derivative | 15,000 | $3.45 Strike: $3.45 | $51,750.00 |
DisclosureSEC source: 0001209191-17-050275 · doc4.xml · derivative · entry 5 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2019-03-05 F3 · derivative.exercise_date: On March 5, 2014, Jennifer Balliet was granted 15,000 stock options which vested ratably over the first three anniversary dates of the grant date. Read SEC document |
| August 24, 2017 Filed Aug 25, 2017 18:44 UTC | NEOGENOMICS INC NEO · Entity 2096 | OtherStock Option (Right to Buy) · Derivative | 7,500 | $3.76 Strike: $3.76 | $28,200.00 |
DisclosureSEC source: 0001209191-17-050275 · doc4.xml · derivative · entry 4 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2018-04-16 F2 · derivative.exercise_date: On April 16, 2013, Jennifer Balliet was granted 7,500 stock options which vested ratably over the first three anniversary dates of the grant date. Read SEC document |
| August 24, 2017 Filed Aug 25, 2017 18:44 UTC | NEOGENOMICS INC NEO · Entity 2096 | Disposition to issuerCommon Stock | 22,500 | $9.38 | $211,050.00 |
DisclosureSEC source: 0001209191-17-050275 · doc4.xml · nonDerivative · entry 3 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Average price of shares sold Read SEC document |
| August 24, 2017 Filed Aug 25, 2017 18:44 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 7,500 | $3.76 | $28,200.00 |
DisclosureSEC source: 0001209191-17-050275 · doc4.xml · nonDerivative · entry 2 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 24, 2017 Filed Aug 25, 2017 18:44 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 15,000 | $3.45 | $51,750.00 |
DisclosureSEC source: 0001209191-17-050275 · doc4.xml · nonDerivative · entry 1 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 22, 2017 Filed Jun 26, 2017 21:32 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 10,723 | $8.49 | $91,038.27 |
DisclosureSEC source: 0001209191-17-041859 · doc4.xml · nonDerivative · entry 1 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| May 26, 2017 Filed May 30, 2017 21:06 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 3,334 | $7.50 | $25,005.00 |
DisclosureSEC source: 0001209191-17-036156 · doc4.xml · nonDerivative · entry 1 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,049 Read SEC document |
| May 25, 2017 Filed May 30, 2017 21:06 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantRestricted Stock · Derivative | 20,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-036156 · doc4.xml · derivative · entry 7 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F6 · security: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. F7 · derivative.exercise_date: Restricted stock will vest as follows; 6,666 units will vest on May 25, 2018 and 6,667 units will vest on May 25, 2019 and 2020. F8 · derivative.expiration_date: These restricted stock units will terminate upon the earliest of death, termination of employment or the last vesting date. Read SEC document |
| April 28, 2017 Filed May 2, 2017 20:39 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $7.52 Strike: $7.52 | $451,200.00 |
DisclosureSEC source: 0001209191-17-029216 · doc4.xml · derivative · entry 6 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2022-04-28 F5 · derivative.exercise_date: On April 28, 2017, Jennifer Balliet was granted 60,000 stock options. The options vest ratably over the first three anniversaries of the grant date. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 23:43 UTC | NEOGENOMICS INC NEO · Entity 2096 | OtherStock Option (Right to Buy) · Derivative | 6,250 | $1.69 Strike: $1.69 | $10,562.50 |
DisclosureSEC source: 0001209191-17-015446 · doc4.xml · derivative · entry 2 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,250 shares Expires 2017-04-12 F1 · derivative.exercise_date: On April 12, 2012, Jennifer Balliet was granted 12,500 stock options. One quarter of these options vested immediately and the remaining options vested on the next three anniversary dates of the grant date. Jennifer Balliet previously exercised 6,250 of these options and is currently exercising the balance. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 23:43 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 6,250 | $1.69 | $10,562.50 |
DisclosureSEC source: 0001209191-17-015446 · doc4.xml · nonDerivative · entry 1 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,383 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 07, 2016 Filed Oct 11, 2016 20:44 UTC | NEOGENOMICS INC NEO · Entity 2096 | OtherStock Option (Right to Buy) · Derivative | 3,334 | $1.10 Strike: $1.10 | $3,667.40 |
DisclosureSEC source: 0001209191-16-145592 · doc4.xml · derivative · entry 2 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,334 shares Expires 2016-10-14 F1 · derivative.exercise_date: On October 14, 2011, Jennifer Balliet was granted 10,000 stock options. The options vest ratably over the first three anniversaries of the grant date. Read SEC document |
| October 07, 2016 Filed Oct 11, 2016 20:44 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 3,334 | $1.10 | $3,667.40 |
DisclosureSEC source: 0001209191-16-145592 · doc4.xml · nonDerivative · entry 1 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,133 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.